Ratings Life Science REIT plc

Equities

LABS

GB00BP5X4Q29

Delayed London S.E. Other stock markets 04:14:49 26/06/2024 pm IST			5-day change	1st Jan Change
33.65 ^GBX	-0.74%		+1.50%	-46.52%

27/03	Jefferies Downgrades Life Science REIT to Hold from Buy, Cuts PT	MT
27/03	Sorted renews M&S deal; Tribe completes drill build	AN

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company's profit outlook over the next few years is a strong asset.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
The company's attractive earnings multiples are brought to light by a P/E ratio at 10.94 for the current year.
The company is one of the best yield companies with high dividend expectations.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

One of the major weak points of the company is its financial situation.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Residential REITs

	1st Jan change	Capi.	ESG Refinitiv
LIFE SCIENCE REIT PLC	-46.52%	15Cr	-
AVALONBAY COMMUNITIES, INC.	+9.12%	2.9TCr	A-
EQUITY RESIDENTIAL	+12.15%	2.6TCr	B
INVITATION HOMES INC.	+4.19%	2.18TCr	B-
ESSEX PROPERTY TRUST, INC.	+11.16%	1.77TCr	B+
MID-AMERICA APARTMENT COMMUNITY, INC.	+4.95%	1.65TCr	B
SUN COMMUNITIES, INC.	-10.94%	1.48TCr	C
UDR INC.	+6.61%	1.34TCr	B
AMERICAN HOMES 4 RENT	+0.81%	1.33TCr	B
EQUITY LIFESTYLE PROPERTIES, INC.	-8.93%	1.2TCr	B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes